Phase IV multicenter, prospective, open-label clinical trial of cenegermin (rhNGF) for stage 1 neurotrophic keratopathy (DEFENDO)
P Hamrah, M Massaro-Giordano, D Schanzlin… - Ophthalmology and …, 2024 - Springer
Introduction Cenegermin is approved for treatment of neurotrophic keratopathy (NK) and has
been studied in patients with stage 2 or 3 NK. This study evaluated the efficacy and safety of …
been studied in patients with stage 2 or 3 NK. This study evaluated the efficacy and safety of …
[引用][C] Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO)
PHMMG David, SEHGB Giovanni, GG Pasedis